Showing results (2921-2930 of 5,702) with videos related to
Sort By:
Pageof 571
The Oncologist|May 27, 2017
Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!Tamila L Kindwall-Keller, Karen K BallenThe Oncologist|May 27, 2017
A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell CancerCristian Lolli, Valentina Gallà, Giuseppe Schepisi, et al.The Oncologist|June 9, 2017
Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging SystemMariana Chavez-MacGregor, Elizabeth A Mittendorf, Christina A Clarke, et al.The Oncologist|June 9, 2017
Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular CarcinomaGhassan K Abou-Alfa, Jean-Frederic Blanc, Steven Miles, et al.The Oncologist|September 16, 2016
Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate CancerEmmanuel S Antonarakis, Chandtip Chandhasin, Erica Osbourne, et al.The Oncologist|April 19, 2022
Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial CarcinomaTomi Jun, Noah M Hahn, Guru Sonpavde, et al.The Oncologist|March 11, 2022
Homologous Recombination Deficiency: Concepts, Definitions, and AssaysMark D Stewart, Diana Merino Vega, Rebecca C Arend, et al.The Oncologist|March 11, 2022
The Impact of Breast Cancer Treatment Delays on Survival Among South African WomenYoanna S Pumpalova, Oluwatosin A Ayeni, Wenlong Carl Chen, et al.The Oncologist|March 11, 2022
BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal CancerElaine Tan, Junmin Whiting, Hao Xie, et al.The Oncologist|March 11, 2022
A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract CarcinomaCecilia Monge, Erica C Pehrsson, Changqing Xie, et al.Pageof 571